A randomized trial to assess the efficacy of interferon-alpha daily in combination with ribavirin in the treatment of naive patients with chronic hepatitis C
| Autor: | S. Kanatakis, I. Ketikoglou, D. Tsantoulas, G. Anagnostopoulos, M. Raptopoulou, Vana Sypsa, G. Hatzis, I. Vafiadis, L. Sidiropoulos, N. C. Tassopoulos, Angelos Hatzakis |
|---|---|
| Rok vydání: | 2003 |
| Předmět: |
Adult
Male medicine.medical_specialty Time Factors Adolescent Alpha interferon Hepacivirus Antiviral Agents Gastroenterology law.invention Therapy naive chemistry.chemical_compound Randomized controlled trial Chronic hepatitis law Virology Internal medicine Ribavirin medicine Humans Adverse effect Aged Hepatology business.industry Interferon-alpha Hepatitis C Chronic Middle Aged Viral Load Discontinuation Treatment Outcome Infectious Diseases chemistry Immunology Drug Therapy Combination Female business Viral load |
| Zdroj: | Journal of Viral Hepatitis. 10:383-389 |
| ISSN: | 1365-2893 1352-0504 |
| DOI: | 10.1046/j.1365-2893.2003.00439.x |
| Popis: | Summary. A randomized trial was conducted to assess the efficacy of interferon-alpha (IFN) daily in combination with ribavirin in 301 naive patients with chronic hepatitis C (CHC). Patients were randomized to receive ribavirin 1.2 g daily (QD) for 48 weeks with either IFN 5 MU (thrice weekly) TIW for 8 weeks followed by IFN 3 MU TIW for 40 weeks (IFN TIW, n = 154) or IFN 5 MU QD for 8 weeks followed by IFN 3 MU QD for 16 weeks followed by IFN 3 MU TIW for 24 weeks (IFN QD, n = 147). Treatment discontinuation rates, because of adverse events, were similar in the two arms (14.9% in IFN TIW and 14.3% in IFN QD, P = 0.87). The proportion of patients with sustained virological response (SVR) was 27.9% for patients treated TIW and 38.8% for those treated QD (P = 0.046). According to logistic regression analysis, patients in the IFN QD arm had 1.7 times higher probability of achieving SVR, than those receiving IFN TIW (P = 0.038). Low baseline viral load (P = 0.017) and genotype non-1 (P = 0.036) were associated with higher SVR rates. Combination of IFN/ribavirin for 48 weeks is more effective when IFN is administered daily for the first 24 weeks in naive patients with CHC. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|